401 related articles for article (PubMed ID: 28416241)
1. Circulating tumor DNA-From bench to bedside.
Lim JSJ; Janku F; Yap TA
Curr Probl Cancer; 2017; 41(3):212-221. PubMed ID: 28416241
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
3. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
Junqueira-Neto S; Batista IA; Costa JL; Melo SA
Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
[TBL] [Abstract][Full Text] [Related]
4. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
5. Fusion genes as biomarkers in pediatric cancers: A review of the current state and applicability in diagnostics and personalized therapy.
Vellichirammal NN; Chaturvedi NK; Joshi SS; Coulter DW; Guda C
Cancer Lett; 2021 Feb; 499():24-38. PubMed ID: 33248210
[TBL] [Abstract][Full Text] [Related]
6. Identification and Use of Personalized Genomic Markers for Monitoring Circulating Tumor DNA.
Chen Y; George AM; Olsson E; Saal LH
Methods Mol Biol; 2018; 1768():303-322. PubMed ID: 29717450
[TBL] [Abstract][Full Text] [Related]
7. Technical considerations for circulating tumor DNA detection in oncology.
Franczak C; Filhine-Tresarrieu P; Gilson P; Merlin JL; Au L; Harlé A
Expert Rev Mol Diagn; 2019 Feb; 19(2):121-135. PubMed ID: 30648442
[TBL] [Abstract][Full Text] [Related]
8. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types.
Shu Y; Wu X; Tong X; Wang X; Chang Z; Mao Y; Chen X; Sun J; Wang Z; Hong Z; Zhu L; Zhu C; Chen J; Liang Y; Shao H; Shao YW
Sci Rep; 2017 Apr; 7(1):583. PubMed ID: 28373672
[TBL] [Abstract][Full Text] [Related]
10. Genetic profiling of cancer with circulating tumor DNA analysis.
Lu L; Bi J; Bao L
J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
[TBL] [Abstract][Full Text] [Related]
11. Monitoring Melanoma Using Circulating Free DNA.
Diefenbach RJ; Lee JH; Rizos H
Am J Clin Dermatol; 2019 Feb; 20(1):1-12. PubMed ID: 30374893
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor DNA: A Step into the Future of Cancer Management.
Fernandes Marques J; Pereira Reis J; Fernandes G; Hespanhol V; Machado JC; Costa JL
Acta Cytol; 2019; 63(6):456-465. PubMed ID: 30852572
[TBL] [Abstract][Full Text] [Related]
13. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
Alix-Panabières C; Pantel K
Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
[TBL] [Abstract][Full Text] [Related]
14. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids.
Okajima W; Komatsu S; Ichikawa D; Miyamae M; Ohashi T; Imamura T; Kiuchi J; Nishibeppu K; Arita T; Konishi H; Shiozaki A; Morimura R; Ikoma H; Okamoto K; Otsuji E
World J Gastroenterol; 2017 Aug; 23(31):5650-5668. PubMed ID: 28883691
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
Chen X; Wang L; Lou J
Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
[TBL] [Abstract][Full Text] [Related]
16. Grail to pour $1 billion into blood test to detect early cancer.
Sheridan C
Nat Biotechnol; 2017 Feb; 35(2):101-102. PubMed ID: 28178244
[No Abstract] [Full Text] [Related]
17. Circulating-tumor DNA as an early detection and diagnostic tool.
Butler TM; Spellman PT; Gray J
Curr Opin Genet Dev; 2017 Feb; 42():14-21. PubMed ID: 28126649
[TBL] [Abstract][Full Text] [Related]
18. ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality.
Salati M; Venetis K; Fassan M; Malapelle U; Pagni F; Sajjadi E; Fusco N; Ghidini M
Future Oncol; 2021 Nov; 17(33):4607-4618. PubMed ID: 34406032
[TBL] [Abstract][Full Text] [Related]
19. [Moving towards a personalized oncology: The contribution of genomic techniques and artificial intelligence in the use of circulating tumor biomarkers].
Perrier A; Hainaut P; Guenoun A; Nguyen DP; Lamy PJ; Guerber F; Troalen F; Denis JA; Boissan M
Bull Cancer; 2022 Feb; 109(2):170-184. PubMed ID: 35034786
[TBL] [Abstract][Full Text] [Related]
20. A high-throughput protocol for isolating cell-free circulating tumor DNA from peripheral blood.
Pandoh PK; Corbett RD; McDonald H; Alcaide M; Kirk H; Trinh E; Haile S; MacLeod T; Smailus D; Bilobram S; Mungall AJ; Ma Y; Moore RA; Coope R; Zhao Y; Jones SJ; Holt RA; Karsan A; Morin RD; Marra MA
Biotechniques; 2019 Feb; 66(2):85-92. PubMed ID: 30744412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]